I make a donation

ARMADA

Effects of Enoxaparine, Dalteparine and NFH on the activation markers of red blood cells in patients presenting an unstable angor or an acute coronary syndrome

Terminée

Pod'casts Interview d'experts

Bourses ACTION & PHRA 2022

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

21e Colloquium (14 mars 2023)
Inscrivez-vous dès maintenant !

objectif

Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction.

date de réalisation

2001

nombre de patients

141

nombre de centres participants

Monocentric

type de financement

Private (Sanofi-Aventis)

Publication

Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study)
Gilles Montalescot, Claire Bal-dit-Sollier, Daniela Chibedi, Jean-Philippe Collet, Thierry Soulat, Miles Dalby, Rémi Choussat, Ariel Cohen, Michel Slama, Phillipe-Gabriel Steg, Jean-Luc Dubois-Randé, Jean-Philippe Metzger, François Tarragano, Jean L Guermonprez, Ludovic Drouet, ARMADA Investigators
Publicated in The American Journal of Cardiology

Autres études

ARCACHON

En cours

To demonstrate the non-inferiority of a strategy of simple clinical follow-up (without non-invasive stress testing) in asymptomatic CAD patients with a prior history of coronary revascularization comp...

EDUC-DAI

En cours

Impact of therapeutic education on the quality of life and the anxiety of patients with a defibrillator.

ABYSS

En cours

Phase 4 trial, evaluating the interest of betablocking treatment in the long term treatment of non-complicated myocardial infarct.